Hu, Hongxiang <br/><br/>
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.  [electronic resource] 

 -  Journal of controlled release : official journal of the Controlled Release Society  Dec 2015 
 - 189-200 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-4995 
<br/><br/><label>Standard No.: </label>10.1016/j.jconrel.2015.10.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B--antagonists & inhibitors<br/>Administration, Oral<br/>Animals<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Cell Survival--drug effects<br/>Delayed-Action Preparations<br/>Dose-Response Relationship, Drug<br/>Drug Carriers<br/>Drug Combinations<br/>Drug Compounding<br/>Drug Synergism<br/>Female<br/>G2 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Hydrogels<br/>Injections, Intralesional<br/>Injections, Intravenous<br/>Lapatinib<br/>MCF-7 Cells<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Nanoparticles<br/>Nanotechnology<br/>Paclitaxel--administration & dosage<br/>Poloxamer--chemistry<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Solubility<br/>Technology, Pharmaceutical--methods<br/>Temperature<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays